Company profile
Chongqing Precision Biotech Co., Ltd
Privately held: no public share price
Assets
(4 total)
4Total Assets
0Approved
0Phase 3 / Filed
4Phase 1–2 / Early
2Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Phase 1/2 | BCMACell therapy | Multiple Myeloma | |
| Phase 1/2 | CD123Cell therapy | Acute Myeloid Leukemia | |
| Phase 1 | CD123 | Acute Myeloid Leukemia | |
| Phase 1 | BCMA; CD70Cell therapy | Multiple Myeloma |
Upcoming events
Research
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.